Fosfomycin Sodium

Captisol-enabled™ Topiramate Injection shown to be a substitute for an oral dose on a one-to-one basis LONDON--(BUSINESS WIRE)-- Ligand Pharmaceuticals Inc. Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on Captisol-enabled™ Topiramate Injection (IV topiramate), a potential replacement therapy for the treatment of certain emergent neurological conditions, including epilepsy, when oral administration is not feasible. The poster was featured at the 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference in London, England. The authors presented modeling and simulations of IV topiramate dosing based on previous studies conducted by UMN faculty in healthy research participants and patients. In addition, preliminary pharmacokinetic data was presented from 25 healthy participants in a CURx ongoing randomized, single-center, open-label, cross-over clinical study for an investigational intravenous (IV) formulation of topiramate, an antiseizure and anti-migraine medication. “The IV formulation of topiramate can be used as replacement therapy; but additionally, small studies in neonates and patients with prolonged seizures indicate it may have a role in treating these conditions if future studies demonstrate benefit,” said James Cloyd, Pharm.D., Director of the Center for Orphan Drug Research at the University of Minnesota College of Pharmacy, co-author of the poster, and a principal investigator on several IV topiramate studies. “Based on our research, we believe clinicians can now properly dose IV topiramate in a variety of clinical situations, including the use of loading doses to rapidly attain targeted plasma drug concentrations in patients when there is a delay in initiating replacement therapy, in patients who are getting topiramate for the first time, and in those taking a co-medication that increases the elimination of topiramate.” “This poster incorporates preliminary pharmacokinetic data from our recent study in healthy research subjects in which an intravenous dose of topiramate was compared to a dose of oral topiramate to assess safety and the dose of the IV topiramate needed to replicate the plasma concentrations following oral administration,” commented Bernard King, M.D., Chief Medical Officer of CURx and co-author of the poster. “Our findings confirm that IV topiramate can be substituted for an oral dose on a one-to-one basis, thus simplifying replacement therapy.” IV topiramate is an investigational formulation of topiramate designed for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients and treatment of epilepsy patients in an emergency care setting who are unable to take oral topiramate. Ligand licensed the rights to the IV formulation of topiramate from UMN and entered into a global license agreement with CURx Pharmaceuticals to further develop and commercialize the product. IV topiramate has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and Ligand is entitled to net milestone payments and a mid-single-digit royalty on global sales. “Our longtime partners are making much-needed progress for people managing epilepsy, and it is exciting to see that,” said James Pipkin, Ph.D., Vice President of New Product Development at Ligand. “The availability of an injectable topiramate formulation will make it possible to ensure continuity of therapy. Captisol is what enables this and other new formulations, which give patients more options and flexibility when it comes to maintaining their medication regimens.” Abstract 305 “A Comparison of IV and Oral Topiramate Pharmacokinetics in Healthy Participants, Patients with Migraines, and Patients with Epilepsy with or without Concomitant Enzyme-Inducing Drugs” was presented by the poster co-authors at the University of Minnesota College of Pharmacy. About Captisol® Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Captisol was invented and initially developed by scientists in the laboratories of Dr. Valentino Stella, University Distinguished Professor at the University of Kansas' Higuchi Biosciences Center, for specific use in drug development and formulation. This unique technology has enabled several FDA-approved products, including Amgen's Kyprolis®, Baxter's NEXTERONE, Acrotech Biopharma's EVOMELA®, Sage Therapeutics' ZULRESSO®, Gilead’s VEKLURY®, and Merck's NOXAFIL®. There are more than 40 active Captisol-enabled™ partnered programs in various stages of development. More information is available at . About Ligand Pharmaceuticals Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International. For more information, please visit . Follow Ligand on X @Ligand_LGND. We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts. About the University of Minnesota The University of Minnesota System, with campuses in Crookston, Duluth, Morris, Rochester, and the Twin Cities, is driven by a singular vision of excellence. We are proud of our land-grant mission of world-class education, groundbreaking research, and community-engaged outreach, and we are unified in our drive to serve Minnesota. Visit system.umn.edu. About CURx Pharmaceuticals CURx Pharmaceuticals is a specialty pharmaceutical company that licenses, develops and commercializes products that address unmet medical needs. The company is focused on searching for and licensing candidates for development based on sound scientific rationale; strong preclinical and clinical study results; defined regulatory pathway to approval; robust intellectual property protection; and defined market need, and to date has licensed three mid- to late-stage molecules. CURx Pharmaceuticals’ lead clinical asset is Fosfomycin Tobramycin for Inhalation (FTI), which is being developed as a treatment for patients with Cystic Fibrosis. For more information visit . Forward-Looking Statements This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include: the potential that topiramate injection can benefit patients who would otherwise be treated via oral administration; and the potential royalties to be paid on sales of topiramate injection by CURx Pharmaceuticals. Actual events or results may differ from Ligand’s or its partner’s expectations due to risks and uncertainties inherent in Ligand’s and its partner’s business, including, without limitation: CURx Pharmaceuticals may not be able to successfully commercialize topiramate injection which will depend on a number of factors including coverage and reimbursement levels from governmental authorities and health insurers as well as market acceptance by healthcare providers; the market size for topiramate injection may be smaller than estimated; Ligand is dependent on CURx Pharmaceuticals for the commercialization of topiramate injection; and other risks described in Ligand’s prior press releases and filings with the Securities and Exchange Commission available at . Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

2024.3.1-2 • 中国南京2024MAH&DDS制剂合作大会展位号：D35号展位分布▼关于江苏开元医药有限公司江苏开元医药有限公司2008年成立于江苏南京市，现有员工500余人，全资子公司7家。是集生物医药研发、生产、贸易于一体的综合性生物医药国际化企业。从事仿制药一致性评价、改良新药和创新药开发、CRO和MAH等研发业务，拥有医药中间体、原料药、成品药等数个CDMO生产基地。公司以实业做支撑，以研发带动贸易，以贸易促进发展；坚持以客户为中心，以提升企业价值导向，努力为客户提供优质、高效的服务和技术支持，凭借品质高、服务优、品牌好获得更加广阔的发展空间，在国际国内生物医药健康领域拥有较高的知名度和良好信誉。公司主要产品覆盖医药中间体、原料药、成品药及医疗器械等，产品销行美国、欧洲、俄罗斯、印度、中东、非洲、亚太、南美等120余个国家或地区，与5000多个客户形成长期的合作关系。公司年出口额超2亿美元，年销售额近15亿元，连续10年被中国医保商会授予“西成药出口十强企业”，连续8年跻身“中国医药国际化百强企业”。同时，开元医药还是中国医药保健品进出口商会副会长单位。关于江苏开元药业有限公司江苏开元药业有限公司是开元医药子公司，致力于药物研发。拥有4000平方米的研发中心，百余人核心技术团队，专业从事化学小分子创新药开发、仿制药一致性评价、CRO和MAH等研发业务。与中国药科大学、南京中医药大学等多家院校、科研单位建立了产学研合作关系，与国药集团、广药集团、国邦集团、鼎泰药研集团等国内知名药企达成医药研发战略合作。公司获得了作为上市许可持有人（MAH）的《药品生产许可证》B证，荣获国家“高新技术企业”认定。公司建立了江苏省企业研究生工作站，获得了国家知识产权贯标单位、江苏省科技服务业百强机构、江苏省高新技术产业开发区瞪羚企业、仿制药一致性评价南京市工程技术研究中心、南京市工程研究中心、南京市信用管理示范企业等荣誉称号。01生产实力江苏中泰药业有限公司位于南京经开区，计划建设占地2万平方米的大型化学药物研发中心和制剂生产车间，剂型包括口服固体制剂、口服溶液、吸入制剂、注射剂、外用药、抗肿瘤制剂。江苏贝佳制药有限公司位于江苏泰州的“中国医药城”，是开元医药的制剂生产基地之一，主要业务包括出口受托生产，MAH受托生产等。拥有片剂、硬胶囊剂(含头孢菌素类)、散剂、口服溶液剂生产许可证，其中片剂、硬胶囊剂(含头孢菌素类)、口服溶波剂通过GMP符合性检查。同时具备颗粒剂、头孢干混悬剂生产条件，具备年产10亿粒胶囊、5亿片剂、3000万瓶口服溶液剂的生产能力。可同时满足国内外客户大批量的药品委托加工生产。开元制药（安徽）有限公司位于安徽宿州经开区，占地300亩，是开元医药生产基地之一，总投资10亿元人民币。一期建设项目实施“年产600吨磷霉素左磷右胺盐、250吨磷霉素钙、50吨磷霉素钠、50吨磷霉素氨丁三醇及1000kg蔗糖八硫酸脂盐等”项目，一期项目投产后年产值5亿元，二期项目筹建中。02研发实力1、专家式研发团队各学科带头人均为知名专业院校毕业，具有十五年以上的行业工作经验，且聘请国内外知名专家学者、前监管机构老师组成顾问团队。2、完善的仪器设备各平台均配备完善、齐全的仪器设备，覆盖研究过程中的多个环节，可为创新药物研发提供良好保障。包括质量研究用仪器，固体制剂、液体制剂设备，稳定性研究设备设施等。3、完善的质量体系配备专门的质量管理团队和质量管理体系，确保试验数据的真实、规范、完整。多次通过国家局现场核查。配有网络版色谱数据采集系统，容灾备份与恢复系统，集成化管理信息系统，数据加密等智能化信息系统。4、优质的服务保障每个项目配备专业的项目组，项目负责人进行全流程项目管理，确保项目质量和效率。保持和客户的及时沟通，确保项目交接顺利推进。03六大主营业务★❖ 仿制药研发注册技术服务❖ 新药创制和技术服务❖药品MAH合作、转让❖ 医药中间体定制合成❖ 原料药合作申报❖药品国际注册及销售04六大优势技术平台★❖ BFS液体制剂❖ 微丸型缓释制剂工艺❖ 熔融挤出制剂工艺❖ 制剂逆向工程研究❖ 基因毒/元素杂质研究❖ 药物发现F-IND技术平台05企业荣誉06合作伙伴07项目清单● 制剂清单：（☆为自持产品）● 中间体原料药清单：08联系方式点击下方小程序立即报名↓↓ 关于药融圈 药融圈PRHub旨在帮助生物医药科技型企业进行品牌推广及商务拓展服务，针对客户的真实需求制定系统化解决方案，通过“翻译-降维-场景化”将客户的品牌信息以直白易懂的方式被公众知悉，同时在流量渠道覆盖100万+垂直用户基础上实现合作目的，帮助合作伙伴完成从品牌开始到商务为终的闭环营销服务。我们已经完成了数十场线下1000人规模的生物医药研发类会议，涵盖小分子新药，大分子新药，改良型新药，BD跨境交易等领域，品牌会议包括中国国际生物及化学制药产业大会(6000人以上)，仿制药峰会（600人以上），新药创新者系列峰会（1200人以上），服务了百余家上市/独角兽/生物技术/制药企业。点击阅读原文查看会议详情